Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer

    Novartis will soon launch Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer.

    It's for postmenopausal women whose cancer progresses despite treatment with an antiestrogen such as tamoxifen (Nolvadex).

    Femara is an aromatase inhibitor. Blocking this enzyme inhibits the PRODUCTION of estrogen in peripheral tissues.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote